The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Large Is The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Projected To Become By 2030 Based On Its 2026 Valuation?
The sodium glucose cotransporter 2 (sglt2) inhibitors market size has experienced robust expansion in recent years. This market is expected to increase from $10.96 billion in 2025 to $11.87 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.3%. The historical growth in this sector is primarily due to rising type 2 diabetes cases, unmet glycemic control needs, clinical trial success, physician awareness, and regulatory approvals.
The sodium glucose cotransporter 2 (sglt2) inhibitors market is anticipated to exhibit robust expansion over the coming years. Projections indicate its value will ascend to $16.35 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.3%. This expected increase throughout the forecast period stems from factors such as the recognition of cardio-renal benefits, the expanding aging diabetic demographic, extended reimbursement coverage, the introduction of novel drugs, and increasing penetration into emerging markets. Furthermore, significant trends for this period include the broadening of their use beyond diabetes, a rise in the adoption of combination therapies, an increase in heart failure indications, enhanced safety profiling, and more widespread inclusion in clinical guidelines.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp
Which Market Drivers Are Supporting The Expansion Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
The escalating occurrence of diabetes is anticipated to stimulate the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market. This condition encompasses a range of metabolic illnesses identified by elevated blood sugar levels, stemming from deficiencies in either insulin production, insulin responsiveness, or both. An increase in diabetes diagnoses can be linked to aspects like urban development, psychological strain, environmental contaminants, and insufficient availability of medical care. Sodium glucose cotransporter 2 (SGLT2) inhibitors play a role in managing diabetes by reducing blood glucose through the prevention of glucose reabsorption in the kidneys, thereby promoting its elimination via urine. These inhibitors additionally provide advantages for cardiovascular and kidney health, making them a crucial choice for addressing diabetes and its associated complications. As an illustration, the Office for Health Improvement and Disparities (OHID), a UK-Based English government organization, reported in March 2025 that the proportion of adults aged 17 and over in England diagnosed with type 2 diabetes by GPs reached 7.0% in March 2024, representing an increase from 6.8% in March 2023. Consequently, the growing incidence of diabetes is a significant factor driving the upward trajectory of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.
What Segment Groups Are Identified Within The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
The sodium glucose cotransporter 2 (sglt2) inhibitors market covered in this report is segmented –
1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics
Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure
Which Trends Are Impacting The Growth Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
Leading companies in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are concentrating on developing dual inhibitor therapeutic solutions to improve patient outcomes and manage blood sugar levels. Dual inhibitor therapeutic solutions are treatments that simultaneously target two different sodium-glucose cotransporters (SGLT1 and SGLT2) to enhance their effectiveness in managing conditions such as heart failure and diabetes. For example, in May 2023, Lexicon Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the Food and Drug Administration (FDA) for sotagliflozin, a treatment for heart failure. This first-in-class dual inhibitor of sodium-glucose cotransporters 1 and 2 is a once-daily tablet created to reduce cardiovascular death, heart failure hospitalizations, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Its benefits include decreased renal glucose and sodium reabsorption, resulting in preload and afterload reduction and diminished sympathetic activity.
Which Companies Hold Significant Positions In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
Major companies operating in the sodium glucose cotransporter 2 (sglt2) inhibitors market are Johnson & Johnson Inc., Merck & Co Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma Inc, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co Ltd, Kotobuki Pharmaceutical Co Ltd, Lexicon Pharmaceuticals Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Hanmi Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Mitsubishi Tanabe Pharma Corporation
Read the full sodium glucose cotransporter 2 (sglt2) inhibitors market report here:
How Is The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Distributed Across Key Geographic Regions?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (sglt2) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp
Browse Through More Reports Similar to the Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market 2026, By The Business Research Company
Antidiabetics Global Market Report
https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report
Mtor Inhibitors Global Market Report
https://www.thebusinessresearchcompany.com/report/mtor-inhibitors-global-market-report
Kinase Inhibitors Global Market Report
https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model